Immunotoxins: An update

Gerald R. Thrush, Laura R. Lark, Birgitta C. Clinchy, Ellen S. Vitetta

Research output: Contribution to journalReview articlepeer-review

161 Scopus citations


The use of immunotoxins (ITs) in the therapy of cancer, graft-vs-host disease (GvHD), autoimmune diseases, and AIDS has been ongoing for the past two decades. ITs contain a targeting moiety for delivery and a toxic moiety for cytotoxicity. Theoretically, one molecule of a toxin, routed to the appropriate cellular compartment, will be lethal to a cell. Newly developed MoAbs, toxins, and molecular biological technologies have enabled researchers to construct ITs that can effectively kill many different cell types. In fact, phase I/II clinical trials have given promising results. Although nonspecific toxicity and immunogenicity still limit the use of IT therapy, these agents hold enormous promise in an optimal setting to treat minimal disease.

Original languageEnglish (US)
Pages (from-to)49-71
Number of pages23
JournalAnnual review of immunology
StatePublished - 1996


  • AIDS
  • autoimmune disease
  • bone marrow transplantation
  • cancer
  • immunotherapy

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'Immunotoxins: An update'. Together they form a unique fingerprint.

Cite this